Welcome to our dedicated page for Roivant Sciences Ltd. SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Roivant Sciences Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Roivant Sciences Ltd.'s regulatory disclosures and financial reporting.
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an option exercise and related share sale. On 2026-07-27 he exercised stock options for 200,000 Common Shares at $3.85 per share from a fully vested award, leaving 4,044,834 options of this grant outstanding, expiring April 19, 2032. He then sold 200,000 Common Shares at a weighted average price of $34.95 (with trades between $34.62 and $35.56), with the filing indicating use of a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. is calling a 2026 Annual General Meeting for September 16, 2026 in London to elect two Class II directors (Daniel Gold and Meghan FitzGerald), ratify Ernst & Young LLP as auditor for the fiscal year ending March 31, 2027, and hold a non-binding advisory vote on named executive officer compensation. The Board recommends FOR all three proposals.
The company has an eight‑member, classified Board with three classes and six independent directors2 female6 male directors. Key committees (Audit, Compensation, Nominating and Governance) are fully independent, and the Chair role is separated from the CEO.
Executive pay follows a stated “pay‑for‑performance” philosophy. Fiscal 2025 annual bonuses were tied to corporate goals, which management and the Compensation Committee scored at 128% of target based on clinical, regulatory and other milestones. A multi‑year Senior Executive Compensation Program grants large performance stock unit awards to top executives, vesting only if share‑price hurdles between $15 and $30 are met over a five‑year period and service conditions are satisfied, with additional post‑vesting holding periods. The company also used sizeable one‑time cash retention bonuses, including an aggregate $2.8 million program for the CFO and a separate $7.5 million cash retention award for President and Vant Chair Frank Torti.
At the prior annual meeting, the advisory Say‑on‑Pay vote received 60.9% support, down from 89.3% a year earlier. In response, Roivant engaged with shareholders owning about half of its outstanding shares; investors were generally supportive of the long‑term incentive structure while emphasizing continued execution and adherence to the multi‑year compensation commitments.
Roivant Sciences Ltd. received a notice that affiliate Eric Venker plans to sell 200,000 common shares, expected to be issued from an option exercise granted on 04/20/2022, with a proposed sale date of 07/27/2026 on NASDAQ via wire settlement.
The notice also lists sales during the prior three months: 200,000 common shares on 05/22/2026 for an aggregate value of 6,054,730.92 and another 200,000 common shares on 06/24/2026 for an aggregate value of 6,631,659.08, each by Eric Venker.
MOMTAZEE JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director James C. Momtazee received an award of 405 Common Shares on July 17, 2026 under the Non-Employee Director Compensation Plan at $0.00 per share. The award was fully vested on grant, bringing his directly held stake to 109,810 Common Shares.
Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 543 Common Shares on July 17, 2026 under the company’s Non-Employee Director Compensation Plan. The award was fully vested at grant and increased her directly held stake to 17,017 Common Shares.
Roivant Sciences Ltd. director Oren Ilan received an award of 775 Common Shares on July 17, 2026 at $0.0000 per share under the company’s Non-Employee Director Compensation Plan, fully vested as of the grant date.
After this grant, Ilan directly holds 121,004 Common Shares; the transaction is reported as a grant/award acquisition and was not made under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. director and CEO Matthew Gline reported a routine tax-related share disposition tied to restricted stock units. On the vesting and settlement of previously granted RSUs, the company withheld 76,171 common shares, valued at $35.39 per share, to cover applicable tax obligations through a net settlement. Following this transaction, Gline directly holds 16,659,945 common shares, indicating he retains a substantial equity position in the company and that the reported disposition reflects tax withholding rather than an open-market sale.
Roivant Sciences Ltd. director Meghan Fitzgerald reported an option exercise paired with an open-market sale of common shares. She exercised stock options to acquire 10,000 common shares at $8.80 per share and on the same date sold 10,000 common shares at an average price of $34.90 per share.
Following these transactions, Fitzgerald directly holds 42,963 common shares of Roivant Sciences. The derivative entry shows 38,578 stock options remaining after the exercise, indicating she continues to have a meaningful option position as well as a direct equity stake.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 40,310 common shares withheld on June 30, 2026 to cover tax obligations. The shares were "net settled" from previously granted RSUs when they vested, rather than sold in the open market.
After this tax-withholding disposition, Torti directly holds 13,536,202 common shares, indicating this was a routine compensation-related event rather than a change in his overall investment stance.